{"id":"atezolizumab-tecentriq","safety":{"commonSideEffects":[{"rate":"20–30%","effect":"Fatigue"},{"rate":"15–25%","effect":"Decreased appetite"},{"rate":"10–20%","effect":"Nausea"},{"rate":"10–15%","effect":"Cough"},{"rate":"10–15%","effect":"Dyspnea"},{"rate":"3–5%","effect":"Immune-mediated pneumonitis"},{"rate":"2–4%","effect":"Immune-mediated hepatitis"},{"rate":"1–3%","effect":"Immune-mediated colitis"}]},"_chembl":{"chemblId":"CHEMBL3707227","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atezolizumab binds to programmed death ligand 1 (PD-L1), preventing its interaction with PD-1 and B7.1 receptors on T cells. This blockade restores anti-tumor immune responses by allowing T cells to recognize and eliminate cancer cells. It is used across multiple cancer types where PD-L1 expression correlates with response.","oneSentence":"Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on the immune system to attack cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:52.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer (NSCLC)"},{"name":"Metastatic urothelial carcinoma"},{"name":"Metastatic triple-negative breast cancer"},{"name":"Hepatocellular carcinoma"},{"name":"Small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07155174","phase":"PHASE2","title":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-25","conditions":"Small Cell Lung Cancer","enrollment":180},{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT04524871","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-01","conditions":"Advanced Liver Cancers","enrollment":518},{"nctId":"NCT04310020","phase":"PHASE2","title":"Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-13","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":47},{"nctId":"NCT07113691","phase":"PHASE1","title":"Iadademstat + SBRT With Atezo in ES-SCLC","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-01-20","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":15},{"nctId":"NCT05058651","phase":"PHASE2, PHASE3","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-28","conditions":"Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma","enrollment":189},{"nctId":"NCT07284121","phase":"","title":"A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-17","conditions":"Lung Cancer, Hepatocellular Carcinoma","enrollment":700},{"nctId":"NCT06066138","phase":"PHASE1","title":"A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-04","conditions":"Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04334941","phase":"PHASE2","title":"Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-20","conditions":"Extensive Stage Lung Small Cell Carcinoma","enrollment":103},{"nctId":"NCT07495735","phase":"","title":"Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2026-03-22","conditions":"HCC - Hepatocellular Carcinoma, Atezolizumab and Bevacizumab in Hepatocellular Carcinoma","enrollment":400},{"nctId":"NCT03321643","phase":"PHASE1","title":"Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-18","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT05211323","phase":"PHASE2","title":"A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-07","conditions":"Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer","enrollment":88},{"nctId":"NCT06287775","phase":"PHASE1, PHASE2","title":"Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-08","conditions":"Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":45},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":"Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":120},{"nctId":"NCT07291076","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-03-16","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":129},{"nctId":"NCT04981509","phase":"PHASE2","title":"Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-10","conditions":"Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma","enrollment":65},{"nctId":"NCT05333458","phase":"PHASE2","title":"Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-29","conditions":"Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma","enrollment":27},{"nctId":"NCT07388524","phase":"PHASE3","title":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-09","conditions":"Lung Non-Small Cell Carcinoma","enrollment":336},{"nctId":"NCT05411081","phase":"PHASE2","title":"Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-24","conditions":"Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8","enrollment":200},{"nctId":"NCT03237780","phase":"PHASE2","title":"Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-20","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":72},{"nctId":"NCT04660344","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-03","conditions":"Muscle-invasive Bladder Cancer","enrollment":761},{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT04729959","phase":"PHASE2","title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-11","conditions":"Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma","enrollment":59},{"nctId":"NCT04214262","phase":"PHASE3","title":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-13","conditions":"Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":480},{"nctId":"NCT05286801","phase":"PHASE1, PHASE2","title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-17","conditions":"Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma","enrollment":86},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":"Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":475},{"nctId":"NCT03811002","phase":"PHASE3","title":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-26","conditions":"Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":544},{"nctId":"NCT04402788","phase":"PHASE2, PHASE3","title":"Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-07","conditions":"Extensive Stage Lung Small Cell Carcinoma","enrollment":138},{"nctId":"NCT04432207","phase":"PHASE1","title":"A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2020-11-30","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV","enrollment":24},{"nctId":"NCT03694262","phase":"PHASE2","title":"The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2019-07-19","conditions":"Endometrial Cancer, Uterine Carcinosarcoma","enrollment":30},{"nctId":"NCT07235293","phase":"PHASE2","title":"A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.","status":"RECRUITING","sponsor":"Kahr Bio Australia Pty Ltd","startDate":"2026-01-16","conditions":"Colorectal Cancer","enrollment":90},{"nctId":"NCT04911166","phase":"PHASE1","title":"Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","startDate":"2021-10-14","conditions":"Non-small Cell Lung Cancer","enrollment":13},{"nctId":"NCT04158258","phase":"","title":"A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-02-21","conditions":"Breast Cancer","enrollment":2907},{"nctId":"NCT07059494","phase":"PHASE4","title":"Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-06","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06713798","phase":"PHASE2","title":"Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures","status":"WITHDRAWN","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-01-30","conditions":"Metastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer","enrollment":""},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT06097962","phase":"EARLY_PHASE1","title":"Safety and Efficacy of NK510 to Treat NSCLC","status":"RECRUITING","sponsor":"Base Therapeutics (Shanghai) Co., Ltd.","startDate":"2023-07-01","conditions":"NSCLC","enrollment":12},{"nctId":"NCT04637594","phase":"PHASE3","title":"Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-05-27","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":3},{"nctId":"NCT06133062","phase":"PHASE2","title":"Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-11-16","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":45},{"nctId":"NCT05411133","phase":"PHASE1","title":"Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients","status":"COMPLETED","sponsor":"Arbele Pty Ltd","startDate":"2022-05-30","conditions":"Gastrointestinal Cancer, Cholangiocarcinoma, Liver Cancer","enrollment":33},{"nctId":"NCT04338269","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-28","conditions":"Carcinoma, Renal Cell","enrollment":522},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT04102098","phase":"PHASE3","title":"A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-12-31","conditions":"Carcinoma, Hepatocellular","enrollment":668},{"nctId":"NCT06161532","phase":"PHASE2","title":"Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-01","conditions":"Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder","enrollment":60},{"nctId":"NCT05359861","phase":"PHASE2","title":"Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2022-04-12","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT04789668","phase":"PHASE1, PHASE2","title":"Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-15","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":8},{"nctId":"NCT07195695","phase":"PHASE3","title":"Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-01-16","conditions":"Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT07010497","phase":"PHASE2","title":"A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-03-16","conditions":"Carcinoma, Hepatocellular","enrollment":33},{"nctId":"NCT04902040","phase":"PHASE1, PHASE2","title":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-04-14","conditions":"Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm","enrollment":19},{"nctId":"NCT06496568","phase":"PHASE1","title":"A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":"PIK3CA-Mutated Cancers","enrollment":30},{"nctId":"NCT05142696","phase":"PHASE1, PHASE2","title":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-13","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT04458922","phase":"PHASE2","title":"Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-10-05","conditions":"Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma","enrollment":27},{"nctId":"NCT05528952","phase":"PHASE2","title":"Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-09-27","conditions":"Hepatocellular Carcinoma","enrollment":105},{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT07472517","phase":"PHASE3","title":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-04-10","conditions":"Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)","enrollment":670},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT05468359","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-11-07","conditions":"Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor","enrollment":64},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT05742269","phase":"","title":"Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Karolinska University Hospital","startDate":"2023-07-01","conditions":"Metastatic Triple-Negative Breast Carcinoma","enrollment":3},{"nctId":"NCT07322341","phase":"PHASE2","title":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-06-01","conditions":"Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma","enrollment":32},{"nctId":"NCT05862285","phase":"PHASE3","title":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-06-01","conditions":"Cancer","enrollment":100},{"nctId":"NCT04300647","phase":"PHASE2","title":"A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-06-30","conditions":"Cervical Cancer","enrollment":172},{"nctId":"NCT04919382","phase":"PHASE2","title":"Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Dwight Owen","startDate":"2022-01-26","conditions":"Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma","enrollment":56},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT07193316","phase":"","title":"Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-07-27","conditions":"Hepatocellular Carcinoma, Liver Cirrhosis","enrollment":38},{"nctId":"NCT06157827","phase":"PHASE1, PHASE2","title":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2023-12-08","conditions":"Advanced Neuroendocrine Carcinoma","enrollment":178},{"nctId":"NCT05968326","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-10-18","conditions":"Adenocarcinoma, Pancreatic Ductal","enrollment":260},{"nctId":"NCT05019703","phase":"PHASE2","title":"Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-25","conditions":"Locally Advanced Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma","enrollment":40},{"nctId":"NCT07381634","phase":"PHASE2","title":"The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2026-03-20","conditions":"Hepatocellular Carcinoma (HCC), IrAE","enrollment":134},{"nctId":"NCT03074513","phase":"PHASE2","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-03-03","conditions":"Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma","enrollment":133},{"nctId":"NCT04832854","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-04-23","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":50},{"nctId":"NCT05047250","phase":"PHASE3","title":"A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-14","conditions":"Non-Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT03313804","phase":"PHASE2","title":"Priming Immunotherapy in Advanced Disease With Radiation","status":"COMPLETED","sponsor":"John L. Villano, MD, PhD","startDate":"2017-10-26","conditions":"Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":76},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT07461675","phase":"PHASE3","title":"Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection","status":"NOT_YET_RECRUITING","sponsor":"University of Geneva, Switzerland","startDate":"2026-03-25","conditions":"Hepato Cellular Carcinoma (HCC), Immunotherapy","enrollment":30},{"nctId":"NCT05091567","phase":"PHASE3","title":"A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-11-18","conditions":"Small-Cell Lung Cancer","enrollment":660},{"nctId":"NCT05689671","phase":"PHASE4","title":"Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nikolaj Frost MD","startDate":"2023-12-06","conditions":"Non-Small Cell Lung Cancer Metastatic","enrollment":136},{"nctId":"NCT06254248","phase":"PHASE2","title":"Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-22","conditions":"Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment","enrollment":50},{"nctId":"NCT05665348","phase":"PHASE2, PHASE3","title":"Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2023-03-09","conditions":"HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor","enrollment":229},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT04020809","phase":"PHASE1","title":"Neoadjuvant Atezolizumab in Cutaneous Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2020-09-25","conditions":"Cutaneous Melanoma","enrollment":20},{"nctId":"NCT04589845","phase":"PHASE2","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-01-18","conditions":"Solid Tumors","enrollment":920},{"nctId":"NCT06031441","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-11-27","conditions":"Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors","enrollment":250},{"nctId":"NCT06096779","phase":"PHASE2","title":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2024-07-15","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT04302025","phase":"PHASE2","title":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":99},{"nctId":"NCT04721132","phase":"PHASE2","title":"Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-10","conditions":"Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8","enrollment":16},{"nctId":"NCT04708067","phase":"PHASE1","title":"Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-08-31","conditions":"Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8","enrollment":2},{"nctId":"NCT04563338","phase":"PHASE2","title":"An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-06-04","conditions":"Hepatocellular Carcinoma, Non-small Cell Lung Cancer Metastatic, Liver Metastases","enrollment":36},{"nctId":"NCT06632327","phase":"PHASE3","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-12-11","conditions":"Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":1100},{"nctId":"NCT06646276","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-25","conditions":"Extensive-Stage Small Cell Lung Cancer","enrollment":530},{"nctId":"NCT06823375","phase":"PHASE2","title":"SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2025-07-10","conditions":"HCC","enrollment":40},{"nctId":"NCT04873362","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-04","conditions":"Breast Cancer","enrollment":1188},{"nctId":"NCT05361395","phase":"PHASE1","title":"First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-08-24","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":184},{"nctId":"NCT06537310","phase":"PHASE1","title":"A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-09-16","conditions":"Cancer-Neoplasms","enrollment":34},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT06492954","phase":"PHASE1","title":"Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"Osteosarcoma, Pulmonary Recurrence of Osteosarcoma","enrollment":12},{"nctId":"NCT04138628","phase":"PHASE2","title":"Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jørgen Bjerggaard Jensen","startDate":"2020-03-24","conditions":"Bladder Cancer, Bladder Cancer, Metastatic","enrollment":154},{"nctId":"NCT05681039","phase":"PHASE2","title":"Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-06-02","conditions":"Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Atezolizumab(Tecentriq)","genericName":"Atezolizumab(Tecentriq)","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on the immune system to attack cancer. Used for Metastatic non-small cell lung cancer (NSCLC), Metastatic urothelial carcinoma, Metastatic triple-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}